Source: https://www.law.cornell.edu/cfr/text/42/8.22
Timestamp: 2017-06-26 14:16:29
Document Index: 79402225

Matched Legal Cases: ['art 8', '§ 823', 'art 8', 'art 8', 'art 8', 'art 8', 'art 8', 'art 8']

42 CFR 8.22 - Definitions. | US Law | LII / Legal Information Institute
CFR › Title 42 › Chapter I › Subchapter A › Part 8 › Subpart D › Section 8.22 42 CFR 8.22 - Definitions.
The following definitions apply to this subpart C. (a)Appellant means:
(1) The treatment program which has been notified of its suspension or proposed revocation of its certification under the regulations of this part and has requested a review of the suspension or proposed revocation, or (2) The accreditation body which has been notified of adverse action regarding withdrawal of approval under the regulations of this subpart and has requested a review of the adverse action. (b)Respondent means SAMHSA. (c)Reviewing official means the person or persons designated by the Secretary who will review the suspension or proposed revocation. The reviewing official may be assisted by one or more HHS officers or employees or consultants in assessing and weighing the scientific and technical evidence and other information submitted by the appellant and respondent on the reasons for the suspension and proposed revocation. This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.United States CodeU.S. Code: Title 21 - FOOD AND DRUGS§ 823 - Registration requirements
Title 42 published on 19-Apr-2017 03:51The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 42 CFR Part 8 after this date.2016-09-27; vol. 81 # 187 - Tuesday, September 27, 201681 FR 66191 - Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements
typeregulations.gov FR Doc.2016-23277 RIN0930-AA22 DEPARTMENT OF HEALTH AND HUMAN SERVICES, HHS, Substance Abuse and Mental Health Services Administration (SAMHSA) Final rule. Effective Date: This final rule is effective on October 27, 2016. 42 CFR Part 8 SummaryThis final rule outlines annual reporting requirements for practitioners who are authorized to treat up to 275 patients with covered medications in an office-based setting. This final rule will require practitioners to provide information on their annual caseload of patients by month, the number of patients provided behavioral health services and referred to behavioral health services, and the features of the practitioner&apos;s diversion control plan. These reporting requirements will help the Department of Health and Human Services (HHS) ensure compliance with the requirements of the final rule, “Medication Assisted Treatment for Opioid Use Disorders,” published in the Federal Register on July 8, 2016.
2016-09-09; vol. 81 # 175 - Friday, September 9, 201681 FR 62403 - Medication Assisted Treatment for Opioid Use Disorders; Correction
typeregulations.gov FR Doc.2016-21674 RIN-0930-AA22 Docket No.2016-0001 DEPARTMENT OF HEALTH AND HUMAN SERVICES, Substance Abuse and Mental Health Services Administration, HHS Correcting amendment. Effective on September 9, 2016. 42 CFR Part 8 SummaryThe Health and Human Services Department (HHS) is correcting a final rule that appeared in the Federal Register on July 8, 2016. The final rule increased the maximum number of patients to whom an individual practitioner may dispense or prescribe certain medications, including buprenorphine, from 100 to 275. Practitioners are eligible for the increased patient limit if they have prescribed covered medications to up to 100 patients for at least one year pursuant to secretarial approval, provided that they meet certain criteria and adhere to several additional requirements aimed at ensuring that patients receive the full array of services that comprise evidence-based medication-assisted treatment (MAT) and minimize the risks that medications provided for treatment are misused or diverted. One pathway through which practitioners may become eligible to increase their patient limit is by obtaining additional credentialing from one of several credentialing bodies. In the final rule, the name of one of the credentialing bodies listed was incorrect. This action provides the correct name.
2016-07-08; vol. 81 # 131 - Friday, July 8, 201681 FR 44576 - Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements
typeregulations.gov FR Doc.2016-16069 RIN0930-AA22 DEPARTMENT OF HEALTH AND HUMAN SERVICES, HHS, Substance Abuse and Mental Health Services Administration (SAMHSA) Supplemental notice of proposed rulemaking. To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on August 8, 2016. 42 CFR Part 8 SummaryOn March 30, 2016, the U.S. Department of Health and Human Services (HHS) published a Notice of Proposed Rulemaking (NPRM) to increase the highest patient limit for qualified physicians to treat opioid use disorder under section 303(g)(2) of the Controlled Substances Act (CSA). On July 6, 2016, HHS published a final rule based on the NPRM but delayed finalizing the reporting requirements outlined in the NPRM. In this Supplemental Notice of Proposed Rulemaking (SNPRM), HHS seeks further comment on the same reporting requirements outlined in the NPRM. These reporting requirements would require annual reporting by practitioners who are approved to treat up to 275 patients under subpart F to help HHS ensure compliance with the requirements of the “Medication Assisted Treatment for Opioid Use Disorders” final rule published elsewhere in this issue of the Federal Register . HHS will consider the public comments on this SNPRM as well as any comments already received on the March 30, 2016 NPRM before issuing a final rule pertaining to the reporting requirements.
typeregulations.gov FR Doc.2016-16120 RIN0930-AA22 DEPARTMENT OF HEALTH AND HUMAN SERVICES, HHS, Substance Abuse and Mental Health Services Administration (SAMHSA) Final rule. Effective Date: This final rule is effective on August 8, 2016. 42 CFR Part 8 SummaryThis final rule increases access to medication-assisted treatment (MAT) with buprenorphine and the combination buprenorphine/naloxone (hereinafter referred to as buprenorphine) in the office-based setting as authorized under the United States Code. Section 303(g)(2) of the Controlled Substances Act (CSA) allows individual practitioners to dispense or prescribe Schedule III, IV, or V controlled substances that have been approved by the Food and Drug Administration (FDA). Section 303(g)(2)(B)(iii) of the CSA allows qualified practitioners who file an initial notification of intent (NOI) to treat a maximum of 30 patients at a time. After 1 year, the practitioner may file a second NOI indicating his/her intent to treat up to 100 patients at a time. This final rule will expand access to MAT by allowing eligible practitioners to request approval to treat up to 275 patients under section 303(g)(2) of the CSA. The final rule also includes requirements to ensure that patients receive the full array of services that comprise evidence-based MAT and minimize the risk that the medications provided for treatment are misused or diverted.
2016-03-30; vol. 81 # 61 - Wednesday, March 30, 201681 FR 17639 - Medication Assisted Treatment for Opioid Use Disorders
typeregulations.gov FR Doc.2016-07128 RIN0930-AA22 DEPARTMENT OF HEALTH AND HUMAN SERVICES, HHS, Substance Abuse and Mental Health Services Administration (SAMHSA) Proposed rule. To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on May 31, 2016. 42 CFR Part 8 SummaryThe Secretary of the Department of Health and Human Services (the Secretary) (HHS) proposes a rule to increase the highest patient limit for qualified physicians to treat opioid use disorder under section 303(g)(2) of the Controlled Substances Act (CSA) from 100 to 200. The purpose of the proposed rule is to increase access to treatment for opioid use disorder while reducing the opportunity for diversion of the medication to unlawful use.
2015-06-18; vol. 80 # 117 - Thursday, June 18, 201580 FR 34837 - Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Proposed Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combination as Used in Approved Opioid Treatment Medications; Correction